Sort by
Refine Your Search
-
: Qualifications: Ideal candidates must possess an academic doctoral degree (e.g., PhD, EdD, ScD, OTD) awarded by an institution that is accredited by a USDE-recognized institutional accrediting agency. Candidates
-
students; and engage in program and university committees as appropriate. Requirements: Qualifications: Ideal candidates possess a research doctoral degree (e.g., PhD, DrPH, ScD) awarded by an institution
-
budgetary approval. Requirements: Candidates must hold or have completed all PhD degree requirements by July 1, 2024. Candidates should have research interests in either behavioral, strategy or quantitative
-
compensation and benefits commensurate with qualifications and experience. Requirements: Candidates must have a MD or PhD degree in medicine, science or engineering. Specific areas of focus are biomedical
-
research doctorate (PhD) in public health or related health sciences discipline or a doctorate in public health (DrPH). Preference will be given to candidates who show evidence of a successful research
-
, and inclusion through their research, teaching, mentoring, and service, and through their engagement with fellow faculty, students, and staff. Requirements: Required qualifications: PhD in hand by
-
Education (ACPE). MS and PhD programs in Pharmaceutical Sciences launched in fall 2022 to further advance the School's translational, clinical and outcomes research within the changing landscape of drug
-
be valued. Requirements: A PhD in Physics or a related field and postdoctoral experience are required. Additional Information: The State University of New York is an Equal Opportunity/Affirmative
-
service will be valued. Requirements: A PhD in Physics or a related field, and postdoctoral experience are required. Additional Information: The State University of New York is an Equal Opportunity
-
Education (ACPE). MS and PhD programs in Pharmaceutical Sciences launched in fall 2022 to further advance the School's translational, clinical and outcomes research within the changing landscape of drug